Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

SOUTH SAN FRANCISCO, Calif., April 03, 2024 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in...

Related Keywords

United States ,Jordyn Tarazi ,Michael Fitzhugh ,Lawrence Blatt ,Aligos Therapeutics Inc ,Exchange Commission ,Investor Relations Corporate Communications ,Nasdaq ,Exchange Commission On ,Lifesci Communications ,Chief Executive Officer ,Securities Litigation Reform Act ,Aligo Annual Report ,Investor Relations ,Markets ,